Search results
Results from the WOW.Com Content Network
ATC code C10 Lipid modifying agents is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup C10 is part of the anatomical group C Cardiovascular system. [4]
Fenofibrate (sold under the brand name Tricor among others), is an oral medication of the fibrate class used to treat abnormal blood lipid levels. [3] It is less commonly used compared to statins because it treats a different type of cholesterol abnormality to statins.
ICD-10 is the 10th revision of the International Classification of Diseases (ICD), a medical classification list by the World Health Organization (WHO). It contains codes for diseases, signs and symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or diseases. [1]
Adoption of ICD-10-CM was slow in the United States. Since 1979, the US had required ICD-9-CM codes [11] for Medicare and Medicaid claims, and most of the rest of the American medical industry followed suit. On 1 January 1999 the ICD-10 (without clinical extensions) was adopted for reporting mortality, but ICD-9-CM was still used for morbidity ...
The ICD-10 Clinical Modification (ICD-10-CM) is a set of diagnosis codes used in the United States of America. [1] It was developed by a component of the U.S. Department of Health and Human services, [2] as an adaption of the ICD-10 with authorization from the World Health Organization.
Classification System Detail ICD-9-CM: Volumes 1 and 2 only. Volume 3 contains Procedure codes: ICD-10: The international standard since about 1998 ICPC-2: Also includes reasons for encounter (RFE), procedure codes and process of care
Although Version:2019 was the last update, and ICD-11 is now available, WHO are still accepting data reported using ICD-10 from member states yet to make the switch to ICD-11. ICD-11 (International classification of diseases, 11th revision) – available for reporting data to WHO since 1 January 2022 [ 5 ]
Fenofibrate is a peroxisome proliferator-activated receptor (PPAR) agonist. [2] It activates a type of receptor called the peroxisome proliferator-activated receptor alpha , which is involved in breaking down fat from the diet, especially triglycerides. [ 2 ]